Amneal Pharmaceuticals Inc Class A (AMRX) valuation
Amneal Pharmaceuticals P/E ratio history
Amneal Pharmaceuticals trades at 44.8 times its earnings over the last twelve months and 19.2 times the earnings analysts expect over the next twelve. At its last 3 fiscal year ends its P/E ranged from 7.5 (year to Dec 2020) to 68.4 (year to Dec 2021), with a median of 57.3.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $12.60 | $0.22 | 57.3 | 13.9 |
| Dec 31, 2024 | $7.92 | -$0.38 | n/m | — |
| Dec 31, 2023 | $6.07 | -$0.48 | n/m | 10.4 |
| Dec 31, 2022 | $1.99 | -$0.86 | n/m | — |
| Dec 31, 2021 | $4.79 | $0.07 | 68.4 | 5.4 |
| Dec 31, 2020 | $4.57 | $0.61 | 7.5 | — |
| Dec 31, 2019 | $4.82 | -$2.76 | n/m | — |
| Dec 31, 2018 | $13.53 | -$0.17 | n/m | — |
| Dec 31, 2017 | $16.65 | $0.00 | n/m | — |
| Dec 31, 2016 | $13.25 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Amneal Pharmaceuticals valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Amneal PharmaceuticalsAMRX | $6.86B | 44.8 | 19.2 | 2.2 |
| LantheusLNTH | $6.54B | 24.0 | 17.1 | 4.2 |
| Ligand PharmaceuticalsLGND | $6.47B | 127.1 | 28.5 | 22.3 |
| Hims & Hers HealthHIMS | $6.41B | — | — | 2.5 |
| Rhythm PharmaceuticalsRYTM | $6.34B | — | — | 26.4 |
| Axsome TherapeuticsAXSM | $7.43B | — | — | 9.6 |
| AlkermesALKS | $7.56B | 119.3 | 29.4 | 4.5 |
| Pacs GroupPACS | $7.57B | 28.0 | 18.2 | 1.4 |
| Kodiak SciencesKOD | $6.21B | — | — | — |
| Peer median | 73.6 | 23.4 | 4.5 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: AMRX financials · AMRX returns
No forecast, no recommendation. This page describes Amneal Pharmaceuticals Inc Class A from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.